FluroTech Grants Options to the Board of Directors
April 05 2021 - 7:30PM
FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) is
pleased to announce that it has granted incentive stock options the
Board of Directors to purchase 225,000 common shares of FluroTech
at a price of $0.45 per share for a term of two years in accordance
with FluroTech’s stock option plan. The options will vest monthly
over a 24-month period and have a life of 4 years. The issuance of
the options is subject to final approval by the TSXV.
About
FluroTech (TSXV:
TEST) (OTCQB:
FLURF)
The goal of FluroTech’s research and technology
is to develop detection methods which are sensitive, specific and
easy-to-use. By combining FluroTech’s proprietary
spectroscopy-based technology with laboratory robotics automation
and cloud computing, FluroTech, through the application of its
technology and investment in FluroTest, has created a unique
solution addressing the current and future pandemics. Using
technology that was first developed at the University of Calgary,
the FluroTest SARS-CoV-2 test is designed to identify patients with
active virus infection; this is not necessarily the case for most
of the currently approved tests that are meant to identify patients
with SARS-CoV-2 nucleic acid. FluroTech’s laboratory is led by Dr.
Elmar Prenner, the original developer of the technology. Dr.
Prenner serves as senior science advisor of FluroTech and brings
over 28 years of expertise in fluorescence spectroscopy. To learn
more, visit FluroTech.com
For all investor inquiries:
FluroTech Ltd.
Danny Dalla-Longa, CEO
info@flurotest.com
Cautionary Statement Regarding Forward-Looking
Information
This news release contains "forward-looking
information" within the meaning of Canadian securities legislation.
Forward-looking information generally refers to information about
an issuer’s business, capital, technology or operations that is
prospective in nature, and includes future-oriented financial
information about the issuer’s perspective financial performance or
financial position. The forward-looking information in this news
release includes disclosure about the ability of the Company’s
testing devices to accurately and quickly detect COVID-19 and to
process large numbers of samples in short time frames. The Company
made certain material assumptions, including but not limited to
prevailing market conditions and general business, economic,
competitive, political and social uncertainties. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward-looking statements.
Actual results may vary from the forward-looking
information in this news release due to certain material risk
factors described in the Corporation’s Annual Information Form
under the heading “Risk Factors”, the failure to develop and
commercialize its testing devices in a timely manner or at all. The
Company cautions that the foregoing list of material risk factors
and assumptions is not exhaustive.
The Company assumes no obligation to update or
revise the forward-looking information in this news release unless
it is required to do so under Canadian securities legislation.
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy of
this release.
FluroTech (TSXV:TEST)
Historical Stock Chart
From May 2024 to Jun 2024
FluroTech (TSXV:TEST)
Historical Stock Chart
From Jun 2023 to Jun 2024